A preclinical pharmacokinetic and pharmacodynamic approach to determine a dose of spironolactone for treatment of congestive heart failure in dog

Journal of Veterinary Pharmacology and Therapeutics

Volumn 33, Issue 3, 2010, Pages 260-267

  Guyonnet, J ^a   Elliott, J ^b   Kaltsatos, V ^a  

^a CEVA SANTÉ ANIMALE   (France)

^b ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CANRENONE; POTASSIUM; PRILACTONE; SODIUM; SPIRONOLACTONE; UNCLASSIFIED DRUG; MINERALOCORTICOID ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE MODEL; DRUG ACTIVITY; DRUG CLEARANCE; EXPERIMENTAL DOG; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERALDOSTERONISM; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; POTASSIUM EXCRETION; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; SODIUM EXCRETION; SODIUM URINE LEVEL; TIME TO MAXIMUM PLASMA CONCENTRATION; URINE FLOW RATE; URINE VOLUME; ANIMAL; DOG; DOG DISEASES; DOSE RESPONSE; HEART FAILURE; VETERINARY;

CANIS FAMILIARIS;

ANIMALS; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART FAILURE; HYPERALDOSTERONISM; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; SPIRONOLACTONE;

EID: 77952115844     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2009.01130.x     Document Type: Article

References (23)

1. Brilla, C.G., Pick, R., Tan, L.B., Janicki, J.S. Weber, K.T. (1990) Remodeling of the rat right and left ventricles in experimental hypertension. Circulation Research, 67, 1355 1364.
2. EMEA - European Medicines Agency - Veterinary Medicines (2007) Prilactone®431. EPAR 432 (European Public Assessment Report). Scientific discussion. Available at: http://www.emea.europa.eu/vetdocs/PDFs/EPAR/ prilactone/V-105-PI-en.pdf (accessed June 2007).
3. Haggstrom, J., Hansson, K., Karlberg, B.E., Kvart, C., Madej, A. Olsson, K. (1996) Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation. American Journal of Veterinary Research, 57, 1645 1652.
4. Hofmann, L.M., Chinn, L.J., Pedrera, H.A., Krupnick, M.I. Suleymanov, O.D. (1975) Potassium prorenoate: a new steroidal aldosterone antagonist. The Journal of Pharmacology and Experimental Therapeutics, 194, 450 456.
5. Hofmann, L.M., Weier, R.M., Suleymanov, O.D. Pedrera, H.A. (1977) Mexrenoate potassium: a steroidal aldosterone antagonist and antihypertensive. The Journal of Pharmacology and Experimental Therapeutics, 201, 762 768.
6. Jeunesse, E., Woehrle, F., Schneider, M. Lefebvre, H.P. (2007) Effect of pironolactone on diuresis and urine sodium and potassium excretion in healthy dogs. Journal of Veterinary Cardiology, 9, 63 68.
7. Jones, B. Kenward, M.G. (1998) Designs and analyses for three or more treatments. In Design and Analysis of Cross-Over Trials, 1st edn. Eds Chapman & Hall, pp. 189 241. CRC Press
8. Kagawa, C.M., Bouska, D.J. Anderson, M.L. (1964) Relationship of plasma aldadiene levels and antimineralocorticoid. Effects of spironolactone in the laboratory. Proceeding of the Society for Experimental Biology and Medicine, 115, 837 840.
9. Kalidindi, S.R., Tang, W.H. Francis, G.S. (2007) Drug insight: aldosterone-receptor antagonists in heart failure - the journey continues. Nature Clinical Practice Cardiovascular Medicine, 4, 368 378.
10. Karim, A., Kook, C., Zitzewitz, J., Zagarella, J., Doherthy, M. Campion, J. (1976) Species differences in the metabolism and disposition of spironolactone. Drug Metabolism and Disposition, 4, 547 555.
11. Knowlen, G.G., Kittleson, M.D., Nachreiner, R.F. Eyster, G.E. (1983) Comparison of plasma aldosterone concentration among clinical status groups of dogs with chronic heart failure. Journal of the American Veterinary Medical Association, 183, 991 996.
12. Monnoyer, S. (2003) Developpement and Validation of the Method of Spironolactone and its Metabolites in Plasma of Dogs. Study Report No. MPK/430A/0126. CEVA Santé Animale
13. Pedersen, H.D., Schutt, T., Sondergaard, R., Qvortrup, K., Olsen, L.H. Kristensen, A.T. (2003) Decreased plasma concentration of nitric oxide metabolites in dogs with untreated mitral regurgitation. Journal of Veterinary Internal Medicine, 17, 178 184.
14. Pitt, B. (1995) Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovascular Drugs and Therapy, 9, 145 149.
15. Pitt, B., Zannad, F., Remme, W.J., Cody, R., Castaigne, A., Perez, A., Palensky, J. Wittes, J. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine, 341, 709 717.
16. Robert, V., Heymes, C., Silvestre, J.S., Sabri, A., Swynghedauw, B. Delcayre, C. (1999) Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension, 33, 981 986.
17. Sadee, W., Riegelman, S. Jones, S.C. (1972) Disposition of Tritium-labeled spironolactones in the dog. Journal of Pharmaceutical Sciences, 61, 1132 1135.
18. Struthers, A.D. (2004) The clinical implications of aldosterone escape in congestive heart failure. European Journal of Heart Failure, 6, 539 545.
19. Tan, L.B., Schlosshan, D. Barker, D. (2004) Fiftieth anniversary of aldosterone: from discovery to cardiovascular therapy. International Journal of Cardiology, 96, 321 333.
20. Tilholm, A., Haggstrom, J. Hansson, K. (2001) Effects of dilated cardiomyopathy on the renin-angiotensin-aldosterone system atrial natriuretic peptide activity, and thyroid hormone concentration in dogs. American Journal of Veterinary Research, 62, 961 967.
21. Toutain, P.L. (2002) Pharmacokinetics/pharmacodynamics integration in drug development and dosage regimen optimization for veterinary medicine. American Association of Pharmaceutical Scientists, 4 (Article 38). http://www.aapsj.org/view.asp?art=ps040438 (accessed August 2009).
22. Xiao, U., Li, S., McMahon, E.G., Lala, D.S. Rudolph, A.E. (2005) Molecular mechanisms of mineralocorticoid receptor antagonist by Eplerenone. Mini-Rewiews in Medicinal Chemistry, 5, 709 718.
23. Yamaoka, K., Nakagawa, T. Uno, T. (1978) Statistical moments in pharmacokinetics. Journal of Pharmacokinetics Biopharmaceutics, 6, 547 558.